Core Viewpoint - The self-controllable production of cell culture media is crucial for the high-quality development of the biopharmaceutical industry in China, with Auscan Bio achieving significant breakthroughs in technology and supply chain management, thus reducing costs and enhancing innovation in the sector [1][2]. Industry Overview - The biopharmaceutical industry is a strategic pillar for the nation, with cell culture media being essential for cell growth and directly impacting production efficiency and product quality [1]. - Historically, this key area has been dominated by European and American companies, with domestic prices being 5 to 20 times higher than international markets, increasing cost burdens and supply chain risks for local enterprises [1]. Company Development - Auscan Bio, founded by Luo Shun, has focused on overcoming the "bottleneck" of cell culture media by innovating and industrializing production, aiming to strengthen the foundation of China's biopharmaceutical industry [2]. - Since 2014, Auscan has gradually replaced all raw materials with domestic alternatives, achieving full supply chain independence by 2017, which has significantly reduced costs and stimulated the development of related domestic industries [3]. Market Position - Auscan's subsidiary, Jianshun Bio, has established the world's largest single-line dry powder culture medium production line, surpassing overseas competitors, and has maintained a market-leading position in dry powder culture medium sales since 2017, with sales volumes exceeding 200 tons by 2025 [3]. - Currently, Auscan supplies 60% of the cell culture media in China's commercial biopharmaceutical sector, enabling 80% to 90% of the industry to achieve self-supply, thereby greatly reducing production costs [3]. Strategic Expansion - Auscan is extending its reach into the downstream of the industry chain by building a comprehensive CRDMO platform, which integrates early research and commercial production, ensuring that key raw materials and large-scale production capabilities are controlled internally [4]. - The company has established the largest ADC commercial production base in the Shanghai Free Trade Zone, which has already generated millions in revenue since its launch in August 2023 [4]. Future Outlook - The structural changes in market demand are expected to drive further domestic substitution, with the number of biopharmaceutical products in China projected to increase from 50-100 to over 500 by 2030, potentially leading to a tenfold growth in the culture medium market [5]. - The biopharmaceutical industry in China is transitioning from following innovation to leading it, with ongoing efforts in domestic substitution enhancing competitiveness and securing supply chain safety [5][6]. - Auscan plans to focus on cutting-edge areas such as ADC, AOC, and APC, continuing to enhance production scale and efficiency while promoting high-quality biopharmaceuticals for patients [6].

Group 1: Investment and Financial Trends - As of the end of April this year, Shenzhen's private equity and venture capital funds have invested in 20,400 projects, targeting 12,500 companies nationwide, with a total investment amount of 970.275 billion yuan, showing a year-on-year increase of over 2% in early-stage, small, and hard technology projects [1] - The number of projects directed towards early-stage technology companies and the corresponding investment amount have increased by 3.89% and 3.93% year-on-year, respectively [1] Group 2: Transportation and Technology Innovations - The Hong Kong government has issued its first official taxi fleet license to Star Taxi Service Company for a period of five years, allowing the fleet to provide ride-hailing services [2] - This initiative is part of a series of measures by the Hong Kong government to optimize taxi services, aiming to establish a professional and technology-driven fleet management system [2] Group 3: Healthcare and Pharmaceutical Developments - A hospital in Shenzhen has become the first in the city to prescribe domestically developed weight-loss drugs, Ma Shidu and Te Erbo, which significantly enhance weight loss effects, especially for patients with stubborn obesity [3] - The introduction of these drugs reflects the advancement of China's biopharmaceutical industry's independent innovation capabilities and Shenzhen's pioneering efforts in medical technology applications [3] Group 4: Scientific Research and Development - China's first ocean-class intelligent research vessel, "Tongji," has been officially delivered, marking a significant advancement in marine research capabilities [4] - The vessel, which began construction in April 2024, is a 2,000-ton intelligent comprehensive research ship that will facilitate the transition from basic research to the integration of science and technology [4] Group 5: Market Performance - On July 14, the Shenzhen Composite Index closed at 10,684.52 points, down 0.11% [5] - Notable gainers in the Shenzhen market included Changrong Co. at 9.05 yuan with a rise of 20.03%, and Xinling Electric at 42.13 yuan with a rise of 19.99% [6] - Conversely, leading decliners included Yuandao Communication at 21.60 yuan, down 20.00%, and *ST Zitian at 3.52 yuan, down 17.76% [6]